-
Spark Therapeutics (ONCE) PT Lowered to $64 at BMO Capital
-
Spark Therapeutics (ONCE) PT Raised to $66 at BMO Capital Following 'Sound' Novartis Partnership
-
Spark Therapeutics (ONCE) PT Lowered to $64 at BMO Capital After Luxturna Price, Keeps Outperform
-
Spark Therapeutics (ONCE) PT Lowered to $73 at BMO Capital, But Says Weakness 'Overdone'
-
Spark Therapeutics (ONCE) PT Raised to $101 at BMO Capital
-
Spark Therapeutics (ONCE): Luxturna Briefing Docs Reinforce Jan Approval - BMO
-
Spark Therapeutics (ONCE) PT Raised to $89 at BMO Capital
-
BMO Capital Reiterates Outperform Rating and $69 PT on Spark Therapeutics (ONCE) Following SPK-9001 Data Update
-
BMO Capital Starts Spark Therapeutics (ONCE) at Outperform